Haematologica 2003 - Supplements
Haematologica 2003 - Supplements Haematologica 2003 - Supplements
esponse, dose was reduced to 400 mg/day and combined with dexamethasone (DEX) and/or chemotherapy (CH). All patients, who discontinued THAL for good response and those who reduced dose because unacceptable toxicity, relapsed. Adjuvant biphosphonate therapy was done in all and haematopoietic growth factors when necessary. We evaluated response using the following criteria: Complete Response (CR: ≥ 90% paraprotein reduction, no progression of bone lesions and no anaemia), Major Response (MjR: ≥ 75% and < 90% paraprotein reduction), Partial Response (PR: ≥ 50% and < 75% paraprotein reduction), Minor Response (MnR: ≥ 25% and < 50% paraprotein reduction) and Stable Disease (SD:
platelets of 207 (76-402), B2M of 3.2 (1.5-5.1), CRP of 1.9 (
- Page 189 and 190: plasmids carrying the clonotypic in
- Page 191 and 192: newly diagnosed multiple myeloma as
- Page 193 and 194: 216 Transgenic expression of Myc an
- Page 195 and 196: 221 Prolonged survival in the 5T2MM
- Page 197 and 198: 9. Chemotherapy, maintenance, treat
- Page 199 and 200: 229 EFFECTIVENESS OF STANDARD CHEMO
- Page 201 and 202: 234 Melphalan and Dexamethasone- Is
- Page 203 and 204: Methods. We investigated the VECD p
- Page 205 and 206: 9.2 Renal complications. 243 MERIT
- Page 207 and 208: cost of SRE-related care was $10,24
- Page 209 and 210: those with Hb >13 g/dL. Analysis of
- Page 211 and 212: sustained response, lasting from 52
- Page 213 and 214: proportion of bone abnormality. IgD
- Page 215 and 216: disease. The lack of response to in
- Page 217 and 218: yielding a median of 3x106/kg CD34
- Page 219 and 220: patients(pts) aged ≥60 yrs. We co
- Page 221 and 222: PBSC mobilizing regimen utilizing C
- Page 223 and 224: their leukocytes and platelets. No
- Page 225 and 226: 25 Gy to marrow. The tracer dose wa
- Page 227 and 228: non-CR after the first transplant a
- Page 229 and 230: 296 PERIPHERAL BLOOD STEM CELL TRAN
- Page 231 and 232: References Effect of dose-intensive
- Page 233 and 234: with cyclosporine A and methotrexat
- Page 235 and 236: 11.Role of novel therapies targetin
- Page 237 and 238: 312 Thalidomide as Rescue of Relaps
- Page 239: patients, light chain in 1 patients
- Page 243 and 244: 325 Low Dose Thalidomide plus Dexam
- Page 245 and 246: in 5 pts (11%), M protein decreased
- Page 247 and 248: time from diagnosis was 3.7 years a
- Page 249 and 250: 339 Thalidomide, Clarithromycin and
- Page 251 and 252: 344 COMBINATION OF THALIDOMIDE, DEX
- Page 253 and 254: experienced early death during the
- Page 255 and 256: untreated patients with high tumor
- Page 257 and 258: 357 Thalidomide protects endothelia
- Page 259 and 260: 362 EOSINOPHILIA IS A VERY COMMON F
- Page 261 and 262: 11.5 CC 4047, PS 341 and arsenic tr
- Page 263 and 264: without chromosome 13. Mean IC50 fo
- Page 265 and 266: myeloma patients. Phase I data indi
- Page 267 and 268: 11.6 Other drugs 380 EFFECT OF STI5
- Page 269 and 270: significant inhibition of cell prol
- Page 271 and 272: which acts to prevent the synthesis
- Page 273 and 274: of B and its metabolites, however,
- Page 275 and 276: and 10 months after start of therap
- Page 277 and 278: terminal kinase (JNK) pathway which
- Page 279 and 280: lymphocytes was tested by Ellispot.
- Page 281 and 282: 411 Dendritic Cell-Based Idiotype V
- Page 283 and 284: Author Index Abe M 74 160 Abelman W
- Page 285 and 286: De La Serna J 291 De Laurenzi A P11
- Page 287 and 288: Hull DR 338 Hullen C P10.2.1 Humes
- Page 289 and 290: Morra E 249 280 359 Morris CM 226 M
platelets of 207 (76-402), B2M of 3.2 (1.5-5.1), CRP of 1.9 (
Change language